RE:RE:RE:RE:RE:RE:RE:Institutional buyer or Fund @ $5.50 USBigboyone wrote:
This stoc k does not follow technicals or fundamentals (Overbought or sold). To some degree it wwill follow moving averages..
Stop projecting your own agenda
Fundamentally, ARLZ got pounded this past year because of how "virtual" everything was with M&A plans finalizing many moths out from when it was first announced last year.
Plus all of the external circumstances which add to the "short" thesis having more validity than just holding through the storm and watching your shares heavily depreciate. YTD performance has absolutely sucked and you cannot deny this.
The recent development in the past month is obviously encouraging. More below.
With all the hype we should have been in lows $7.00+, Look at the volume picking up here, Do you know any small shareholder selling before our anticipated aproval date? I dont..Who would be selling here? Who?
Expecting close to 100% from YTD lows on speculation for drug approval? Get your head out of the clouds.
On the other hand, from current price levels and if the drug gets approved, I would not be surprised to see us retest last years highs. It was incredibly irrational that we did 100%+ last year on an M&A announcement, yet, it happened. If Yosprala manages to get approved after how much emphasis has been put into it (coupled with unnsuccesful attempts), more upward movement can be expected because the company has essentially demonstrated they are competent.
Then of course, expectations for earnings of Yosprala (and getting it approved elsewhere) all add further catalysts.
And, any downward price movement that was happening after nice runs in recent weeks were definitely shorts likely aiming to hit stops so more shares can be accumulated. Retail guys are not making those moves, I agree.